2-Methoxy-3,8,9-trihydroxy coumestan: A new synthetic inhibitor of Na +,K+-ATPase with an original mechanism of action

Biochemical Pharmacology

Volumn 66, Issue 11, 2003, Pages 2169-2176

  Carneiro Pôças, Elisa Suzana ^a   Ribeiro Costa, Paulo Roberto ^b   Da Silva, Alcides José Monteiro ^b   Noël, François ^a  

^a Inst de Cie Biomedicas Depto de Bioquim Medica Cidade Universitária   (Brazil)

^b Nucleo de Pesq de Produtos Naturais   (Brazil)

Author keywords

ATPase Na+,K+; Cardiac glycoside; Coumestan; Inotropic

Indexed keywords

2 METHOXY 3,8,9 TRIHYDROXYCOUMESTAN; ADENOSINE TRIPHOSPHATASE (POTASSIUM SODIUM); ADENOSINE TRIPHOSPHATASE (POTASSIUM SODIUM) ALPHA 1; ADENOSINE TRIPHOSPHATASE (POTASSIUM SODIUM) ALPHA 2; ADENOSINE TRIPHOSPHATASE (POTASSIUM SODIUM) ALPHA 3; ADENOSINE TRIPHOSPHATASE (POTASSIUM SODIUM) INHIBITOR; ION; ISOPROTEIN; OUABAIN; UNCLASSIFIED DRUG; VANADIC ACID;

ANALYTIC METHOD; ANIMAL TISSUE; ARTICLE; BINDING ASSAY; BRAIN; CHEMICAL PROCEDURES; COMPLEX FORMATION; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DRUG ACTIVITY; DRUG EFFECT; DRUG MECHANISM; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG SCREENING; DRUG STABILITY; ENZYME CONFORMATION; ENZYME INHIBITION; IC 50; INHIBITION KINETICS; KIDNEY; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN INTERACTION; RAT;

EID: 0242660503     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2003.08.005     Document Type: Article

References (35)

1. Repke K., Portius H.J. Über die identität der ionenpumpen-ATPase in der zellmembran des herzskels mit einem digitalis rezeptorenzym. Experientia. 19:1963;452-458.
2. +-ATPase in the inotropic action of digitalis. Pharmacol. Rev. 29:1977;187-220.
3. Packer M. Consensus recommendations for heart failure. Am. J. Cardiol. 83A(2):1999;1A-38A.
4. +-ATPase: the molecular basis for the hemodynamic effect of digoxin therapy in congestive heart failure. Cardiovasc. Res. 55:2002;710-713.
5. Packer M., Gheorghiade M., Young J.B.et al. Withdrawal of digoxin from patients with chronic heart failure treated with angiotensin-converting-enzyme inhibitors. RADIANCE study. N. Engl. J. Med. 329:1993;1-7.
6. Uretsky B.F., Young J.B., Shahidi F.E., Yellen L.G., Harrison M.C., Jolly M.K. Randomized study assessing the effect of digoxin withdrawal in patients with mild to moderate chronic congestive heart failure: results of the PROVED trial. J. Am. Cell Cardiol. 22:1993;955-962.
7. The Digitalis Investigation Group. The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med 1997;336:525-33.
8. Repke K.R.H., Sweadner K.J., Weiland J., Megges R., Schön R. In search of ideal inotropic steroids: recent progress. Prog. Drug Res. 47:1996;9-52.
9. Gobbini M., Barassi P., Cerri A., De Munari S., Fedrizzi G., Santagostino M., Schiavone A., Torri M., Melloni P. 17r-O-(Aminoalkyl)oxime derivatives of 3,14-dihydroxy-5-androstane and 3-hydroxy-14-oxoseco-D-5- androstane as inhibitors of Na+,K+-ATPase at the digitalis receptor. J. Med. Chem. 44:2001;3821-3830.
10. +-ATPase. J. Med. Chem. 45:2002;189-207.
11. Sevillano L.G., Melero C.P., Caballero E., Tomé F., Lelièvre L.G., Geering K., Crambert G., Carrón R., Medarde M., San Feliciano A. Inotropic activity of hydroindene amidinohydrazones. J. Med. Chem. 45:2002;127-136.
12. Silva A.J.M., Melo P.A., Silva N.M.V., Brito F.V., Buarque C.D., de Souza D.V., Rodrigues V.P., Poças E.S.C., Noël F., Albuquerque E.X., Costa P.R.R. Synthesis and preliminary pharmacological evaluation of coumestans with different patterns of oxygenation. Bioorg. Med. Chem. Lett. 11:2001;283-286.
13. +-ATPase inhibition in microssomes from rat heart. Biochem. Pharmacol. 33:1984;47-53.
14. Lowry O.H., Rosebrough N.J., Farr A.L., Randall R.J. Protein measurement with the folin phenol reagent. J. Biol. Chem. 193:1951;265-275.
15. Fiske C.H., Subbarow Y. The colorimetric determination of phosphorus. J. Biol. Chem. 66:1925;375-392.
16. 2+. Life Sci. 44(22):1989;1677-1683.
17. Silva C.L.M., Cruz H.M., Violante F.A., Cordeiro R.S.B., Martins M.A., Noël F. Formation of a highly stable complex between BN 50730 [tetrahydro-4,7,8,10 methyl-1 (chloro-2 phenyl)-6 (methoxy-4 phenyl-carbamoyl) -9 pyrido [4′,3′-4,5] thieno [3,2-f] triazolo-1,2,4 [4,3-a] diazepine-1,4] and the platelet-activating factor receptor in rabbit platelet membranes. Biochem. Pharmacol. 51:1996;193-196.
18. Schwartz A., Lindenmayer G.E., Allen J.C. The sodium-potassium adenosine triphosphatase: pharmacological physiological and biochemical aspects. Pharmacol. Rev. 27:1975;3-134.
19. +-ATPase. Eur. J. Pharmacol. 111:1985;147-157.
20. +-ATPase from Guinea pig and rat hearts. Braz. J. Med. Biol. Res. 22:1989;433-445.
21. +-ATPase. Biochim. Biophys. Acta. 988:1989;185-220.
22. Jenkinson DH, Barnard EA, Hoyer D, Humphrey PPA, Leff P, Shankley NP. Terms and symbols in quantitative pharmacology. The IUPHAR compendium of receptor characterization and classification. London, UK: IUPHAR Media; 1998. p. 6-20.
23. De Meyts P., Roth J., Neville D., Gavin J.R., Lesniak M.A. Insulin interaction with its receptors: experimental evidence for negative cooperativity. Biochem. Biophys. Res. Commun. 55:1973;161.
24. +-ATPase. Biochim. Biophys. Acta. 694:1982;27-68.
25. +-ATPase isoenzymes of weaned and adult rats. J. Neurochem. 62:1994;1560-1569.
26. Mayol V., Duran M.J., Gerbi A., Dignat-George F., Lèvy S., Sampol J., Maixent J.M. Cholesterol and omega-3 fatty acids inhibit Na, K-ATPase activity in human endothelial cells. Atherosclerosis. 142:1999;327-333.
27. +-ATPase: aspects of the structure-activity relationship and action mechanism. Biochemistry. 15:1976;4951-4956.
28. +-ATPase: aspects of the structure-activity relationship and action mechanism. Life Sci. 45:1989;1111-1117.
29. +-ATPase by flavonoids and their inotropic effect: investigation of the structure-activity relationship. Membr. Cell Biol. 12:1998;27-40.
30. +-ATPase isozymes by LND-623. Biochem. Pharmacol. 42:1991;S223-S224.
31. +-ATPase isoforms and exclusion of cellular sites of contractile control. Cardiovasc. Drugs Ther. 12(6):1998;585-594.
32. +-ATPase. J. Enzyme Inhib. 12:1997;53-58.
33. +-ATPase α2 isoform as a regulator of calcium in heart. Mol. Cell. 3:1999;555-563.
34. Finet M., Godfraind T., Noël F. The inotropic effect of ouabain and its antagonism by dihydroouabain in rat isolated atria and ventricules in relation to specific binding sites. Br. J. Pharmacol. 80:1983;751-759.
35. +-ATPase isozymes. J. Biol. Chem. 275(3):2000;1976-1986.